AB Science SA

AB Science will publish its 2024 annual financial report on May 9, 2025

01 May 2025 04:06:22 By Nasdaq GlobeNewswire

AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia

23 Apr 2025 12:59:03 By Nasdaq GlobeNewswire

AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease

14 Apr 2025 12:02:30 By Nasdaq GlobeNewswire

AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch

04 Mar 2025 02:35:15 By Nasdaq GlobeNewswire

AB Science today provides an update on its masitinib platform

29 Jan 2025 13:03:14 By Nasdaq GlobeNewswire

AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET

24 Jan 2025 12:01:01 By Nasdaq GlobeNewswire

AB Science will participate in the Biomed Forum investors conference

22 Jan 2025 12:59:47 By Nasdaq GlobeNewswire

AB Science provides a summary of the webcast held on December 16, 2024

17 Dec 2024 13:04:08 By Nasdaq GlobeNewswire

AB Science will host a live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET

11 Dec 2024 12:06:34 By Nasdaq GlobeNewswire

AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease

28 Oct 2024 12:47:33 By Nasdaq GlobeNewswire

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

17 Oct 2024 13:28:54 By Nasdaq GlobeNewswire

AB Science: Revenues for the first half of 2024 and update on AB Science’s activities

10 Oct 2024 02:28:04 By Nasdaq GlobeNewswire

AB Science announces a slight delay in the publication of its 2024 half-year financial report

30 Sep 2024 12:33:35 By Nasdaq GlobeNewswire

AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement

26 Sep 2024 02:28:30 By Nasdaq GlobeNewswire

AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024

23 Sep 2024 11:51:06 By Nasdaq GlobeNewswire

AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19

08 Jul 2024 01:56:02 By Nasdaq GlobeNewswire

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

28 Jun 2024 06:31:02 By Nasdaq GlobeNewswire

AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS

31 May 2024 10:30:34 By Nasdaq GlobeNewswire

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

29 May 2024 12:02:52 By Nasdaq GlobeNewswire

AB Science reports its revenues for the year 2023 and provides an update on its activities

15 May 2024 14:16:47 By Nasdaq GlobeNewswire